Drug Trial Radar · NCT00950638
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jul 16, 2009
Primary completion
Mar 24, 2011
Study completion Mar 24, 2011
Sponsor
- Lead sponsor
- Ophthotech CorporationIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).
Conditions
- Dry Age-Related Macular Degeneration
Interventions
Avacincaptad PegolDrug
intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of any dose-limiting toxicity (DLT), safety endpoints include adverse events, vital signs, ophthalmic variables and outcomesTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ophthotech
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.